ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...